iPSC-Derived Thymus Organoids as a Preclinical Platform for Restoring Immune-Aging Capacity and Inducing Antigen-Specific Tolerance

Engineered thymus organoid platforms are being studied preclinically as tools to investigate immune-system aging and antigen-specific tolerance; no human therapy based on this approach is approved or in late-stage clinical trials as of 2026.

Type

evidence-claim

Domain

h10_altered_intercellular_communication

Grade

C+

License

CC BY-NC 4.0

card_id

L-009

hallmarks

h10_altered_intercellular_communication

cluster

clinical_translation

primary_disease_area

longevity_general

evidence_tier

C+

evidence_anchor_count

4

intake_round

R23

intake_date

2026-05-26

related_experts

related_biomarkers

related_interventions

related_trials

collection_pages

/research/hallmarks/h10-altered-intercellular-communication,/research/interventions/immune-aging-platforms

LongProof Longevity Dynamic · LIGHT HOPE / x1000.ai · longevity.x1000.ai · 2026 · source

Read-only aggregated view. Longevity Evidence is the source of record; this catalog shows provenance as-is — no ratings, no reviews.